Von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes

Circulation

Volumn 117, Issue 11, 2008, Pages 1449-1459

  Spiel, Alexander O ^a   Gilbert, James C ^b   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Archemix Corporation   (United States)

Author keywords

Coronary disease; Myocardial infarction; Platelets; Thrombosis; Von Willebrand factor

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 1779; AURINTRICARBOXYLIC ACID; DALTEPARIN; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; HIRUDIN; TENECTEPLASE; TIROFIBAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; VON WILLEBRAND FACTOR RECEPTOR;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; BLOOD CLOT LYSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; HEART INFARCTION; HUMAN; LABORATORY TEST; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POPULATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; ACUTE DISEASE; BLOOD; BLOOD RHEOLOGY; CORONARY ARTERY THROMBOSIS; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; INJURY; METABOLISM; PHYSIOLOGY; RISK FACTOR; RUPTURE; SYNDROME; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; HEMORHEOLOGY; HUMANS; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RISK FACTORS; RUPTURE, SPONTANEOUS; SYNDROME; THROMBOLYTIC THERAPY; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 41649119245     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.722827     Document Type: Review

References (144)

1. Virchow R. In: Gesammalte Abhandlungen zur Wissenschaftlichen Medtzin. Frankfurt, Germany: Medinger Sohn & Co; 1856:219-732.
2. Hollestelle MJ, Thinnes T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, Loskutoff DJ, van Mourik JA. Tissue distribution of factor VIII gene expression in vivo: a closer look. Thromb Haemost. 2001;86:855-861.
3. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993;50:125-134.
4. Jilma B, Pernerstorfer T, Dirnberger E, Stohlawetz P, Schmetterer L, Singer EA, Grasseli U, Eichler HG, Kapiotis S. Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. J Lab Clin Med. 1998;131:151-156.
5. Pernerstorfer T, Stohlawetz P, Kapiotis S, Eichler HG, Jilma B. Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man. Atherosclerosis. 2000;148:43-47.
6. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J. 1993;7:308-316.
7. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A. 1985;82:8752-8756.
8. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood. 1998;92:3684-3693.
9. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255-265.
10. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science. 1985;228:1401-1406.
11. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
12. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939-2950.
13. Bowie EJ, Solberg LA Jr, Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest. 1986;78:26-30.
14. Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A. 1995;92:2428-2432.
15. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, Johnson RC, Hynes RO, Heath M, Lawson CA, Stern DM. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies: a mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest. 1996;97:493-500.
16. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood. 1990;75:688-695.
17. Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB. Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture. Blood. 1982;60:531-534.
18. Chignard M, Balloy V, Renesto P. Leucocyte elastase-mediated release of von Willebrand factor from cultured endothelial cells. Eur Respir J. 1993;6:791-796.
19. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol. 1987;67:193-197.
20. Jilma B, Dirnberger E, Eichler HG, Matulla B, Schmetterer L, Kapiotis S, Speiser W, Wagner OF. Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man. Thromb Haemost. 1997;78:1268-1271.
21. Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest. 1976;57:1618-1625.
22. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-darginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977;1:869-872.
23. Aledort LM. Treatment of von Willebrand's disease. Mayo Clin Proc. 1991;66:841-846.
24. Turitto VT, Weiss HJ, Zimmerman TS, Sussman II. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood. 1985;65:823-831.
25. Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood. 1985;65:85-90.
26. Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood. 1988;72:850-854.
27. Cramer EM, Debili N, Martin JF, Gladwin AM, Breton-Gorius J, Harrison P, Savidge GF, Vainchenker W. Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes. Blood. 1989;73:1123-1129.
28. Ruggeri ZM, Ware J, Ginsburg D. von Willebrand Factor. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. 2nd ed. Baltimore, Md: William & Wilkins; 1998:337ff.
29. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289): slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 2000;275:7539-7546.
30. Bonnefoy A, Yamamoto H, Thys C, Kito M, Vermylen J, Hoylaerts MF. Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood. 2003;101:1375-1383.
31. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: a dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem. 1992;267:11300-11306.
32. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
33. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107:3537-3545.
34. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-297.
35. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood. 2006;108:1903-1910.
36. Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res. 1981;21:689-691.
37. Bendetowicz AV, Wise RJ, Gilbert GE. Collagen-bound von Willebrand factor has reduced affinity for factor VIII. J Biol Chem. 1999;274:12300-12307.
38. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest. 1988;82:1236-1243.
39. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988;263:10451- 10455.
40. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. 2002;41:11065-11070.
41. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039.
42. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432-1436.
43. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
44. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost. 2006;32:456-471.
45. Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971;26:362-369.
46. Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost. 1997;78:930-933.
47. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152-163.
48. Krizek DR, Rick ME. A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res. 2000;97:457-462.
49. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
50. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344-353.
51. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97:953-957.
52. Folsom AR, Conlan MG, Davis CE, Wu KK. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol. 1992;2:481-494.
53. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol. 1997;80:1566-1571.
54. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-3145.
55. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-1108.
56. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-2247.
57. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994;88:601-607.
58. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol. 1999;105:110-116.
59. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17:3321-3325.
60. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation. 2004;109:1343-1348.
61. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:1764-1770.
62. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
63. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186-1193.
64. Goto S, Sakai H, Ikeda Y, Handa S. Acute myocardial infarction plasma augments platelet thrombus growth in high shear rates. Lancet. 1997;349:543-544.
65. Goto S, Sakai H, Goto M, Ono M, Ikeda Y, Handa S, Ruggeri ZM. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation. 1999;99:608-613.
66. Li M, Goto S, Sakai H, Kim JY, Ichikawa N, Yoshida M, Ikeda Y, Handa S. Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction. Thromb Res. 2000;100:251-261.
67. Yamashita A, Sumi T, Goto S, Hoshiba Y, Nishihira K, Kawamoto R, Hatakeyama K, Date H, Imamura T, Ogawa H, Asada Y. Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J Cardiol. 2006;97:26-28.
68. Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 2006;4:114-120.
69. Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res. 2006;118:305-312.
70. Cucuianu MP, Missits I, Olinic N, Roman S. Increased ristocetinco-factor in acute myocardial infarction: a component of the acute phase reaction. Thromb Haemost. 1980;43:41-44.
71. Haines AP, Howarth D, North WR, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Millar Craig MW. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost. 1983;50:800-803.
72. Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med. 1992;93:651-657.
73. Yazdani S, Simon AD, Kovar L, Wang W, Schwartz A, Rabbani LE. Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina. J Am Coll Cardiol. 1997;30:1284-1287.
74. Eto K, Isshiki T, Yamamoto H, Takeshita S, Ochiai M, Yokoyama N, Yoshimoto R, Ikeda Y, Sato T. AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1999;19:877-882.
75. Lip GY, Lydakis C, Nuttall SL, Landray MJ, Watson RD, Blann AD. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. J Intern Med. 2000;248:316-318.
76. Sakai H, Goto S, Kim JY, Aoki N, Abe S, Ichikawa N, Yoshida M, Nagaoka Y, Handa S. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost. 2000;84:204-209.
77. Tanigawa T, Nishikawa M, Kitai T, Ueda Y, Okinaka T, Makino K, Ito M, Isaka N, Ikeda Y, Shiku H, Nakano T. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol. 2000;85:1054-1059.
78. Qi X, Peng Y, Gu J, Li S, Zheng S, Zhang J, Wang T. Inflammatory cytokine release in patients with unstable angina after coronary angioplasty. Jpn Heart J. 2002;43:103-115.
79. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-1397.
80. Lee KW, Blann AD, Lip GY. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol. 2006;111:302-308.
81. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood. 2005;105:526-532.
82. Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol. 2006;106:333-337.
83. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-641.
84. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355.
85. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results: PLAT Study Group: Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb. 1992;12:1063-1070.
86. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol. 2000;20:2019-2023.
87. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost. 2006;4:2547-2552.
88. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006;4:2490-2493.
89. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109:1998-2000.
90. Margulis T, David M, Maor N, Soff GA, Grenadier E, Palant A, Aghai E. The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemost. 1986;55:366-368.
91. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin: French Investigators of the ESSENCE Trial. Circulation. 1998;98:294-299.
92. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol. 2000;36:110-114.
93. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391-394.
94. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J. 2005;26:440-446.
95. Montalescot G, Collet JP, Choussat R, Ankri A, Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol. 2000;72:293-294.
96. Vila V, Martinez-Sales V, Reganon E, Peris E, Perez F, Ruano M, Aznar J. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. Haematologica. 2001;86:729-734.
97. Hodl R, Huber K, Kraxner W, Nikfardjam M, Schumacher M, Fruhwald FM, Zorn G, Wonisch M, Klein W. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol. 2002;89:589-592.
98. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48:2178-2185.
99. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
100. Henriques JP, Zijlstra F, van't Hof AW, de Boer MJ, Dambrink JH, Gosselink M, Hoorntje JC, Suryapranata H. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003;107:2115-2119.
101. Poli A, Fetiveau R, Vandoni P, del Rosso G, D'Urbano M, Seveso G, Cafiero F, De Servi S. Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function. Circulation. 2002;106:313-318.
102. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302-2306.
103. Blann A, Midgley H, Burrows G, Maxwell S, Utting S, Davies M, Waite M, McCollum C. Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis. 1993;4:905-910.
104. Heper G, Murat SN, Durmaz T, Kalkan F. Prospective evaluation of von Willebrand factor release after multiple and single stenting. Angiology. 2004;55:177-186.
105. Kefer JM, Galanti LM, Desmet S, Deneys V, Hanet CE. Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis. 2005;16:505-509.
106. Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T, Jennings LK, Cohen DJ, Morrow DA. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2006;97:1473-1477.
107. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol. 1990;16:1553-1560.
108. Andreotti F, Hackett DR, Haider AW, Roncaglioni MC, Davies GJ, Beacham JL, Kluft C, Maseri A. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemost. 1992;68:678-682.
109. Soskin P, Mossard JM, Arbogast R, Wiesel ML, Grunebaum L, Roul G, Bareiss P, Moulichon ME, Cazenave JP, Sacrez A. Variation in von Willebrand's factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications. Eur Heart J. 1994;15:479-482.
110. Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood. 1992;79:38-44.
111. McGhie AI, McNatt J, Ezov N, Cui K, Mower LK, Hagay Y, Buja LM, Garfinkel LI, Gorecki M, Willerson JT. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation. 1994;90:2976-2981.
112. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, Yoshimoto R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22:187-192.
113. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher. 2002;6:2-4.
114. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. 2008;48:382-392.
115. Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies: clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006;21:1549-1554.
116. Hasper D, Schrage D, Niesporek S, Knollmann F, Barckow D, Oppert M. Extensive coronary thrombosis in thrombotic-thrombocytopenic purpura. Int J Cardiol. 2006;106:407-409.
117. Lapp H, Shin DI, Kroells W, Boerrigter G, Horlitz M, Schley P, Stoerkel S, Guelker H. Cardiogenic shock due to thrombotic thrombocytopenic purpura. Z Kardiol. 2004;93:486-492.
118. Podolsky SH, Zembowicz A, Schoen FJ, Benjamin RJ, Sonna LA. Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med. 1999;123:937-940.
119. Hoylaerts MF, Thys C, Arnout J, Vermylen J. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Blood. 1998;91:2810-2817.
120. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis. 2006;21:175-178.
121. Bronte-Stewart B, Botha MC, Krut LH. ABO blood groups in relation to ischaemic heart disease. BMJ. 1962;1:1646-1650.
122. von Beckerath N, Koch W, Mehilli J, Gorchakova O, Braun S, Schomig A, Kastrati A. ABO locus O1 allele and risk of myocardial infarction. Blood Coagul Fibrinolysis. 2004;15:61-67.
123. McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet. 1990;336:1137-1138.
124. O'Brien JR, Green PJ, Salmon G, Weir P, Colin-Jones D, Arnold M. Desmopressin and myocardial infarction. Lancet. 1989;1:664-665.
125. Lowe GD. Desmopressin and myocardial infarction. Lancet. 1989;1:895-896.
126. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med. 1988;318:121.
127. Ruggeri ZM. von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992;86(suppl):III-26-III-29.
128. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
129. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem. 1989;264:17361-17367.
130. Sobel M, Bird KE, Tyler-Cross R, Marques D, Toma N, Conrad HE, Harris RB. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation. 1996;93:992-999.
131. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
132. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation. 1995;91:1354-1362.
133. Kamat SG, Turner NA, Konstantopoulos K, Hellums JD, McIntire LV, Kleiman NS, Moake JL. Effects of Integrelin on platelet function in flow models of arterial thrombosis. J Cardiovasc Pharmacol. 1997;29:156-163.
134. Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost. 2003;1:2022-2030.
135. Dardik R, Ruggeri ZM, Savion N, Gitel S, Martinowitz U, Chu V, Varon D. Platelet aggregation on extracellular matrix: effect of a recombinant GPIb-binding fragment of von Willebrand factor. Thromb Haemost. 1993;70:522-526.
136. Girma JP, Fressinaud E, Christophe O, Rouault C, Obert B, Takahashi Y, Meyer D. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib. Thromb Haemost. 1992;68:707-713.
137. Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood. 1988;72:1898-1903.
138. Wilson C, Keefe AD. Building oligonucleotide therapeutics using nonnatural chemistries. Curr Opin Chem Biol. 2006;10:607-614.
139. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol. 2006;10:282-289.
140. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost. 1998;79:202-210.
141. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122:165-171.
142. Kageyama S, Yamamoto H, Yoshimoto R. Anti-human von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol. 2000;20:2303-2308.
143. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol. 2002;443:143-149.
144. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116:2678-2686.